Research on China Cardiovascular Drugs Industry

2014-2018
Email: sales@researchbeam.com Toll Free: +1 (855) 711-1555
Reports Overview
Research on China Cardiovascular Drugs Industry, 2014-2018 primarily carries on analyses
on cardiovascular drugs market in the following aspects: market scale, the scale of segment
markets, current competition status and business performance of major drug
manufacturers; meanwhile it makes predictions about prospective market so as to help
investors know this industry well and provide decision-making references for them.

With the aged tendency of population in China and the increasing morbidity of chronic
diseases which have to be treated with medicines for the rest of patients’ life, market scale
of cardiovascular drugs is expanding. This trend has been reflected in recent years. While in
the next few years, with the reform of medical insurance in China and the continuous
standardization of pharmaceutical market as well as the unique curative effect of Chinese
patent medicines, Chinese patents medicines for cardiovascular diseases will enjoy a
promising development prospect.

In 2013 market scale of cardiovascular drugs has reached CNY 17.8 billion in China. At
present cardiovascular diseases have a relatively higher morbidity rate among all diseases
and also is a kind of disease that is hard to be cured. Along with the changes of people’s life-
styles, the difficulties in curing cardiovascular diseases are becoming more prominent.
Reports Overview
The compound annual growth rate of cardiovascular diseases is 21.6%, and the prevalence
rate of cardiovascular diseases will increase further because of the improvements on
people’s living standards, the changes of life styles and increasing aging population. The
market will be expanded.

On the other hand, patients with cardiovascular diseases have stood at 290 million, and
patients with chronic diseases who have received systematic treatment account for a small
proportion. In the next ten years, there is a potential for the growth in cardiovascular
diseases treatment field. It is predicted that the growth rate will maintain more than 20%
from 2014 to 2018. Huidian Research estimates that the sales scale of cardiovascular drugs
in China in 2014 will reach about CNY 22 billion, and the figure will be CNY 45 billion by
2018.

Read Complete Report with TOC:
http://www.researchbeam.com/research-on-china-cardiovascular-drugs-industry-2014-
2018-market
Table of Contents
1. Overview of China Cardiovascular Drugs Industry
1.1 Prevalence Situation of Cardiovascular Diseases in China
1.1.1 Definition of Cardiovascular Diseases
1.1.2 Number of Cardiovascular Patients and Death Situation
1.1.3 Hazards of Cardiovascular Diseases
1.2 Definition of Cardiovascular Drugs Industry

2. Development Environment of China Cardiovascular Drugs Industry
2.1 China’s Economic Development Environment
2.2 Policy Environment Influencing Industry Development

3. Development Status of Pharmaceuticals Industry
3.1 Performance of Major Economic Indicator
3.2 Main Influence Factors
3.3 Key Task Progress of the 12th Five-Year Plan
3.4 Situation Forecast in 2014

Table of Contents
4. Current Situation of Cardiovascular Drugs Market
4.1 Development Situation of International Cardiovascular Drugs Market
4.2 Development Status of China Cardiovascular Drugs Market
4.3 Competitive Landscape in China

5. Competitive Analysis of China Cardiovascular 7 Drugs
5.1 Market Profile of Cardiovascular 7 Drugs
5.2 Market Analysis of Medicines for Heart Disease
5.2.1 Alprostadil
5.2.2 Creatine Phosphate
5.2.3 Complex Coenzyme
5.3 Market Analysis of Medicines for Peripheral Vascular Expansion
5.3.1 Cinepazide
5.3.2 Fasudil
5.3.3 Ligustrazine
5.4 Market Analysis of Medicines for Renin-angiotensin System

Table of Contents
5.4.1 Valsartan
5.4.2 Irbesartan
5.4.3 Losartan
5.4.4 Telmisartan
5.4.5 Benazepril
5.5 Market Analysis of Calcium Channel Blockers (CCB)
5.5.1 Amlodipine
5.5.2 Nifedipine
5.5.3 Felodipine
5.5.4 Levamlodipine
5.5.5 Nimodipine
5.6 Market Analysis of Antilipemic Agents
5.6.1 Atorvastatin Calcium
5.6.2 Simvastatin
5.6.3 Pravastatin
5.7 Market Analysis of?-Blocking Agents
5.7.1 Bisoprolol

Table of Contents
5.7.2 Metoprolol
5.7.3 Carvedilol
5.7.4 Esmolol
5.8 Market Analysis of Antihypertensive Drugs
5.9 Market Analysis of Diuretics
5.9.1 Torasemide
5.9.2 Indapamide

6. Competitive Analysis of Chinese Patent Medicines for Cardiovascular System
6.1 Market Profile of Chinese Patent Medicines for Cardiovascular Diseases
6.2 Competitive Landscape
6.3 Chinese Patent Medicines for Cardiovascular Diseases in Hospitals of Nine Large Cities
6.4 Main Chinese Patent Medicines for Cardiovascular Diseases
6.4.1 Ginkgo Injection
6.4.2 Danhong Injection
6.4.3 Xueshuantong Injection

Table of Contents
6.4.4 Sanqi Panax Notoginseng Injection
6.4.5 Cerecarton Capsules

7. Leading Enterprises of Cardiovascular Drugs Industry
7.1 International Leading Brands and Their Investments in China
7.1.1 Pfizer
7.1.2 Novartis
7.1.3 Merck & Co., Inc.
7.1.4 Sanofi
7.1.5 Roche Holding Ltd.
7.2 Leading Enterprises of Cardiovascular Medicines in China
7.2.1 Beijing SL PHARM
7.2.2 SALUBRIS
7.2.3 TASLY Pharm.
7.2.4 Taiantang Group
7.2.5 Guizhou Yibai Pharmaceutical Co., Ltd.


Table of Contents
To Get Purchase Enquiry of Report:
http://www.researchbeam.com/research-on-china-cardiovascular-drugs-industry-2014-
2018-market/purchase-enquiry

Similar market studies:

• Nanobiotix (NANO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

• Merrion Pharmaceuticals Plc (3MP) - Pharmaceuticals & Healthcare - Deals and
Alliances Profile

• NeuroVive Pharmaceutical AB (NVP) - Pharmaceuticals & Healthcare - Deals and
Alliances Profile
Contact us
Cathy Viber
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Direct: +1 (617) 674-4143
Toll Free: +1 (855) 711-1555
Fax: +1 (855) 550-5975
Web: www.researchbeam.com
Email: sales@researchbeam.com